½ÃÀ庸°í¼­
»óǰÄÚµå
1566939

¹ÙÀÌ¿À¹ðÅ© °ü¸® ½Ã½ºÅÛ ½ÃÀå : »ùÇà À¯Çüº°, ¿ëµµº° - ¼¼°è ±âȸ ºÐ¼® ¹× »ê¾÷ ¿¹Ãø(2024-2033³â)

Biobank Management Systems Market By Sample Type , By Application : Global Opportunity Analysis and Industry Forecast, 2024-2033

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Allied Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 280 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¹ÙÀÌ¿À¹ðÅ© °ü¸® ½Ã½ºÅÛ ½ÃÀåÀÇ 2023³â ½ÃÀå ±Ô¸ð´Â 21¾ï ´Þ·¯·Î 2033³â¿¡´Â 46¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2024³âºÎÅÍ 2033³â±îÁö 8.3%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¹ÙÀÌ¿À¹ðÅ© °ü¸® ½Ã½ºÅÛÀº »ý¹°ÇÐÀû »ùÇà ¹× °ü·Ã µ¥ÀÌÅÍ °ü¸®¿Í °ü·ÃµÈ º¹ÀâÇÑ ÇÁ·Î¼¼½º¸¦ °£¼ÒÈ­Çϱâ À§ÇØ °í¾ÈµÈ ÷´Ü Ç÷§ÆûÀÔ´Ï´Ù. ÀÌ ½Ã½ºÅÛÀº À¯ÀüüÇÐ, ¸ÂÃãÀÇ·á, ½Å¾à°³¹ß µî ´Ù¾çÇÑ ºÐ¾ßÀÇ ¿¬±¸°³¹ß¿¡ ÇʼöÀûÀÎ »ý¹°ÇÐÀû ½Ã·áÀÇ È¿À²ÀûÀÎ ¼öÁý, º¸°ü, °Ë»öÀ» º¸ÀåÇÕ´Ï´Ù. º¸°ü °ü¸®»Ó¸¸ ¾Æ´Ï¶ó ±âÁõÀÚ µ¿ÀÇ °ü¸®, µ¥ÀÌÅÍ ÇÁ¶óÀ̹ö½Ã º¸È£, ½Ã·áÀÇ ÃÖÀû º¸°üÀ¸·Î ¾çÁúÀÇ ¿¬±¸ Áö¿ø µîÀÇ ±â´Éµµ Æ÷ÇÔÇÕ´Ï´Ù. ¸¹Àº ÀÏ»ó ¾÷¹«¸¦ ÀÚµ¿È­ÇÔÀ¸·Î½á ¹ÙÀÌ¿À¹ðÅ© °ü¸® ½Ã½ºÅÛÀº ½Ç¼ö¸¦ ÁÙÀ̰í, ½Ã°£À» Àý¾àÇϸç, ¹ÙÀÌ¿À¹ðÅ©ÀÇ È¿À²¼ºÀ» ³ôÀ̰í, ¿¬±¸ÀÚ¿Í ÀÇ·áÁøÀÌ Á¶»ç ¹× ÀÓ»ó½ÃÇè¿¡ ÇÊ¿äÇÑ »ùÇÿ¡ ½±°Ô Á¢±ÙÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù.

¿¬±¸ ¹× °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿¡¼­ »ý¹°ÇÐÀû »ùÇÿ¡ ´ëÇÑ ¼ö¿ä°¡ ±ÞÁõÇÔ¿¡ µû¶ó ¹ÙÀÌ¿À¹ðÅ© ¼ö°¡ Áõ°¡ÇÏ´Â °ÍÀº ¼¼°è ¹ÙÀÌ¿À¹ðÅ© °ü¸® ½Ã½ºÅÛ ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â Áß¿äÇÑ ¿äÀÎÀ¸·Î, 2021³â ¹Ì±¹ »ý¸í°øÇÐÁ¤º¸¼¾ÅÍÀÇ Á¶»ç¿¡ µû¸£¸é ¹ÙÀÌ¿À¹ðÅ© ¼ö°¡ ¸Å³â ¾à 10%¾¿ Áõ°¡ÇÏ¿© ¹ÙÀÌ¿À¹ðÅ© Ȱµ¿ÀÌ Å©°Ô ¼ºÀåÇϰí ÀÖ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ÀºÇà Ȱµ¿ÀÌ ´«¿¡ ¶ç°Ô ¼ºÀåÇϰí ÀÖ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. À¯Àüü ¿¬±¸°¡ È®´ëµÊ¿¡ µû¶ó ´ë·®ÀÇ »ý¹°ÇÐÀû µ¥ÀÌÅÍ¿Í »ùÇÃÀ» °ü¸®Çϰí Á¤¸®ÇÏ´Â °í±Þ ½Ã½ºÅÛ¿¡ ´ëÇÑ Çʿ伺ÀÌ ³ô¾ÆÁö¸é¼­ ¹ÙÀÌ¿À¹ðÅ© °ü¸® ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼ö¿ä°¡ ´õ¿í Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä°¡ ±ÞÁõÇÏ´Â °Íµµ ½ÃÀå ¼ºÀå¿¡ Å©°Ô ±â¿©Çϰí ÀÖ½À´Ï´Ù. 2023³â The Lancet¿¡ °ÔÀçµÈ ¿¬±¸¿¡ µû¸£¸é, °³ÀÎ ¸ÂÃãÇü ÀÇ·á´Â »ý¹°ÇÐÀû »ùÇÃÀÇ È¹µæ ¹× ºÐ¼®¿¡ Å©°Ô ÀÇÁ¸Çϰí ÀÖ¾î È¿À²ÀûÀÎ ¹ÙÀÌ¿À¹ðÅ© °ü¸® ½Ã½ºÅÛÀÇ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿Í ¸ÂÃãÇü Ä¡·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁü¿¡ µû¶ó ¹ÙÀÌ¿À¹ðÅ© °ü¸® ½Ã½ºÅÛÀÇ Ã¤ÅÃÀÌ 25% Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¹ÙÀÌ¿À¹ðÅ© °ü¸® ½Ã½ºÅÛ Ã¤ÅÃÀÌ 25% Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù. ¶ÇÇÑ, COVID-19 ÆÒµ¥¹ÍÀº ¿¬±¸¸¦ À§ÇÑ »ý¹°ÇÐÀû »ùÇÃÀ» °ü¸®ÇÏ°í ¹èÆ÷ÇÏ´Â È¿À²ÀûÀÎ ¹ÙÀÌ¿À¹ðÅ© ½Ã½ºÅÛÀÇ Á߿伺À» °­Á¶ÇÏ¸ç ¹ÙÀÌ¿À¹ðÅ© °ü¸® ½Ã½ºÅÛ µµÀÔ¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁ® ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, µ¥ÀÌÅÍ ºÐ¼®, ¿¹Ãø ¸ðµ¨¸µ ¹× ÀÚµ¿È­µÈ ÀÇ»ç°áÁ¤À» °­È­Çϱâ À§ÇØ AI ¹× ML ±â¼úÀ» ¹ÙÀÌ¿À¹ðÅ© °ü¸® ½Ã½ºÅÛ¿¡ ÅëÇÕÇÏ´Â °ÍÀÌ ÇöÀç ½ÃÀå ¼ºÀåÀ» Å©°Ô Áõ°¡½ÃŰ´Â Ãß¼¼ÀÔ´Ï´Ù. Ŭ¶ó¿ìµå ±â¹Ý ¹ÙÀÌ¿À¹ðÅ© °ü¸® ½Ã½ºÅÛÀº È®Àå °¡´ÉÇÑ ½ºÅ丮Áö ¼Ö·ç¼Ç, µ¥ÀÌÅÍ Á¢±Ù¼º Çâ»ó, ¿¬±¸ÆÀ °£ Çù¾÷ °­È­ µîÀÇ ÀÌÁ¡À» Á¦°øÇÏ´Â µî Ŭ¶ó¿ìµå ±â¹Ý ¹ÙÀÌ¿À¹ðÅ© °ü¸® ½Ã½ºÅÛÀÇ Ã¤ÅÃÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ¹ÙÀÌ¿À¹ðÅ© °ü¸® ½Ã½ºÅÛÀÇ ÀåÁ¡¿¡ ´ëÇÑ ÀνÄÀÌ Á¦ÇÑÀûÀ̰í, µµÀÔ ¹× À¯Áöº¸¼ö¸¦ À§ÇÑ Àü¹® Áö½ÄÀÌ ºÎÁ·ÇØ ½ÃÀå ¼ºÀå¿¡ °É¸²µ¹ÀÌ µÇ°í ÀÖ½À´Ï´Ù. º¸¾È ´ëÃ¥Àº ¹ßÀüÇϰí ÀÖÁö¸¸, µ¥ÀÌÅÍ À¯Ãâ°ú ¹Î°¨ÇÑ »ý¹°ÇÐÀû µ¥ÀÌÅÍ¿¡ ´ëÇÑ ¹«´Ü ¾×¼¼½º¿¡ ´ëÇÑ ¿ì·Á´Â ±â°üµéÀÌ µðÁöÅÐ °ü¸® ½Ã½ºÅÛÀ» Àü¸éÀûÀ¸·Î µµÀÔÇÏ´Â °ÍÀ» ÁÖÀúÇÏ°Ô ¸¸µå´Â ¿äÀÎÀÔ´Ï´Ù. ¹Ý¸é, µ¥ÀÌÅÍ °ü¸®, ÀÚµ¿È­, Ŭ¶ó¿ìµå ÄÄÇ»ÆÃ ºÐ¾ßÀÇ ±â¼ú Çõ½ÅÀº ¹ÙÀÌ¿À¹ðÅ© °ü¸® ½Ã½ºÅÛÀÇ ¿ª·®À» Çâ»ó½Ã۰í ÀÖÀ¸¸ç, ¿¹Ãø ±â°£ µ¿¾È ¼¼°è ½ÃÀå È®´ë¿¡ À¯¸®ÇÑ ±âȸ¸¦ Á¦°øÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ, Á¤ºÎ ±â°ü, ¿¬±¸ ±â°ü ¹× ºñ»óÀå ±â¾÷ÀÇ ¹ÙÀÌ¿À¹ðÅ· ¹× °ü·Ã ±â¼ú¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡´Â ¹ÙÀÌ¿À¹ðÅ© °ü¸® ½Ã½ºÅÛ ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

¼¼°è ¹ÙÀÌ¿À¹ðÅ© °ü¸® ½Ã½ºÅÛ »ê¾÷Àº »ùÇà À¯Çü, ¿ëµµ, Áö¿ªÀ¸·Î ±¸ºÐµË´Ï´Ù. ½Ã·á À¯Çüº°·Î´Â Èí¼ö¼º ÀÎü Á¶Á÷ ¹× Àå±â ½Ã·á, ½Ä¹° ¹× µ¿¹° ½Ã·á, ¹Ì»ý¹° ½Ã·á·Î ³ª´¹´Ï´Ù. ¿ëµµº°·Î´Â Àç»ýÀÇ·á, »ý¸í°úÇÐ ¿¬±¸, Àӻ󿬱¸, ȯ°æ¿¬±¸·Î ³ª´¹´Ï´Ù. Áö¿ªº°·Î´Â ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, LAMEA·Î ºÐ¼®µË´Ï´Ù.

ÁÖ¿ä Á¶»ç °á°ú

»ùÇà À¯Çüº°·Î´Â ÀÎü Á¶Á÷ ¹× Àå±â »ùÇà ºÐ¾ß°¡ 2023³â ½ÃÀå Á¡À¯À² 1À§¸¦ Â÷ÁöÇß½À´Ï´Ù.

¿ëµµº°·Î´Â ÀÓ»ó ¿¬±¸ ºÎ¹®ÀÌ 2023³â ÁÖ¿ä ÁÖÁÖ°¡ µÇ¾ú½À´Ï´Ù.

Áö¿ªº°·Î´Â ºÏ¹Ì°¡ 2023³â ½ÃÀå ÁÖµµ±ÇÀ» Àå¾ÇÇß½À´Ï´Ù.

º» º¸°í¼­¿¡¼­ °¡´ÉÇÑ Ä¿½ºÅ͸¶ÀÌ¡(Ãß°¡ ºñ¿ë ¹× ÀÏÁ¤ÀÌ ÀÖ½À´Ï´Ù.)

  • ±ÔÁ¦ °¡À̵å¶óÀÎ
  • °í°´ÀÇ °ü½É»ç¿¡ µû¸¥ ±â¾÷ ÇÁ·ÎÆÄÀÏ Ãß°¡
  • ±¹°¡º° ¶Ç´Â Áö¿ªº° Ãß°¡ ºÐ¼® - ½ÃÀå ±Ô¸ð ¹× Àü¸Á
  • ±â¾÷ °³¿ä È®Àå ¸ñ·Ï
  • °ú°Å ½ÃÀå µ¥ÀÌÅÍ
  • ÁÖ¿ä ±â¾÷ÀÇ ¼¼ºÎ Á¤º¸(À§Ä¡, ¿¬¶ôó, °ø±Þ¾÷ü/º¥´õ ³×Æ®¿öÅ© µî Æ÷ÇÔ, ¿¢¼¿ Çü½Ä)

¸ñÂ÷

Á¦1Àå ¼Ò°³

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå »óȲ

  • ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§
  • ÁÖ¿ä Á¶»ç °á°ú
    • ÁÖ¿ä ÅõÀÚ ±âȸ
    • ÁÖ¿ä ¼º°ø Àü·«
  • Porter's Five Forces ºÐ¼®
  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ

Á¦4Àå ¹ÙÀÌ¿À¹ðÅ© °ü¸® ½Ã½ºÅÛ ½ÃÀå : »ùÇà À¯Çüº°

  • ½ÃÀå °³¿ä
  • Èí¼ö¼º Àΰ£ Á¶Á÷ Àå±â »ùÇÃ
  • ½Ä¹° µ¿¹° »ùÇÃ
  • ¹Ì»ý¹° »ùÇÃ

Á¦5Àå ¹ÙÀÌ¿À¹ðÅ© °ü¸® ½Ã½ºÅÛ ½ÃÀå : ¿ëµµº°

  • ½ÃÀå °³¿ä
  • Àç»ýÀÇ·á
  • »ý¸í°úÇÐ Á¶»ç
  • ÀÓ»ó ¿¬±¸
  • ȯ°æ Á¶»ç

Á¦6Àå ¹ÙÀÌ¿À¹ðÅ© °ü¸® ½Ã½ºÅÛ ½ÃÀå : Áö¿ªº°

  • ½ÃÀå °³¿ä
  • ºÏ¹Ì
    • ÁÖ¿ä ½ÃÀå µ¿Çâ°ú ±âȸ
    • ¹Ì±¹ÀÇ ¹ÙÀÌ¿À¹ðÅ© °ü¸® ½Ã½ºÅÛ ½ÃÀå
    • ij³ª´ÙÀÇ ¹ÙÀÌ¿À¹ðÅ© °ü¸® ½Ã½ºÅÛ ½ÃÀå
    • ¸ß½ÃÄÚÀÇ ¹ÙÀÌ¿À¹ðÅ© °ü¸® ½Ã½ºÅÛ ½ÃÀå
  • À¯·´
    • ÁÖ¿ä ½ÃÀå µ¿Çâ°ú ±âȸ
    • µ¶ÀÏÀÇ ¹ÙÀÌ¿À¹ðÅ© °ü¸® ½Ã½ºÅÛ ½ÃÀå
    • ÇÁ¶û½ºÀÇ ¹ÙÀÌ¿À¹ðÅ© °ü¸® ½Ã½ºÅÛ ½ÃÀå
    • ¿µ±¹ÀÇ ¹ÙÀÌ¿À¹ðÅ© °ü¸® ½Ã½ºÅÛ ½ÃÀå
    • ÀÌÅ»¸®¾ÆÀÇ ¹ÙÀÌ¿À¹ðÅ© °ü¸® ½Ã½ºÅÛ ½ÃÀå
    • ½ºÆäÀÎÀÇ ¹ÙÀÌ¿À¹ðÅ© °ü¸® ½Ã½ºÅÛ ½ÃÀå
    • ±âŸ À¯·´ÀÇ ¹ÙÀÌ¿À¹ðÅ© °ü¸® ½Ã½ºÅÛ ½ÃÀå
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÁÖ¿ä ½ÃÀå µ¿Çâ°ú ±âȸ
    • ÀϺ»ÀÇ ¹ÙÀÌ¿À¹ðÅ© °ü¸® ½Ã½ºÅÛ ½ÃÀå
    • Áß±¹ÀÇ ¹ÙÀÌ¿À¹ðÅ© °ü¸® ½Ã½ºÅÛ ½ÃÀå
    • È£ÁÖÀÇ ¹ÙÀÌ¿À¹ðÅ© °ü¸® ½Ã½ºÅÛ ½ÃÀå
    • ÀεµÀÇ ¹ÙÀÌ¿À¹ðÅ© °ü¸® ½Ã½ºÅÛ ½ÃÀå
    • Çѱ¹ÀÇ ¹ÙÀÌ¿À¹ðÅ© °ü¸® ½Ã½ºÅÛ ½ÃÀå
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¹ÙÀÌ¿À¹ðÅ© °ü¸® ½Ã½ºÅÛ ½ÃÀå
  • ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ÁÖ¿ä ½ÃÀå µ¿Çâ°ú ±âȸ
    • ºê¶óÁúÀÇ ¹ÙÀÌ¿À¹ðÅ© °ü¸® ½Ã½ºÅÛ ½ÃÀå
    • »ç¿ìµð¾Æ¶óºñ¾ÆÀÇ ¹ÙÀÌ¿À¹ðÅ© °ü¸® ½Ã½ºÅÛ ½ÃÀå
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹ÀÇ ¹ÙÀÌ¿À¹ðÅ© °ü¸® ½Ã½ºÅÛ ½ÃÀå
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ¹ÙÀÌ¿À¹ðÅ© °ü¸® ½Ã½ºÅÛ ½ÃÀå

Á¦7Àå °æÀï »óȲ

  • ¼Ò°³
  • ÁÖ¿ä ¼º°ø Àü·«
  • ÁÖ¿ä 10°³ ±â¾÷ Á¦Ç° ¸ÅÇÎ
  • °æÀï ´ë½Ãº¸µå
  • °æÀï È÷Æ®¸Ê
  • ÁÖ¿ä ±â¾÷ÀÇ Æ÷Áö¼Å´×(2023³â)

Á¦8Àå ±â¾÷ °³¿ä

  • Agilent Technologies, Inc.
  • CloudLIMS Technologies Pvt. Ltd.
  • AgileBio SARL
  • Modul-Bio
  • Autoscribe Informatics
  • Krishagni Solutions Pvt Ltd
  • Information Management Services, Inc
  • Technidata Inc
  • Qiagen N.V
  • Azenta Inc
ksm 24.10.29

The biobank management systems market was valued at $2.1 billion in 2023, and is projected to reach $4.6 billion by 2033, growing at a CAGR of 8.3% from 2024 to 2033.

Biobank management system is an advanced platform designed to streamline the complex processes involved in managing biological samples and associated data. These systems ensure efficient collection, storage, and retrieval of biological specimens, which are essential for research and development in various fields, including genomics, personalized medicine, and drug discovery. In addition to storage management, these systems include features for managing consent from donors, handling data privacy, and supporting high-quality research by ensuring that samples are stored under optimal conditions. By automating many routine tasks, biobank management systems reduce errors, save time, and improve the efficiency of biobanks, making it easier for researchers and medical professionals to access the samples they need for studies and clinical trials.

Increase in number of biobanks, driven by surge in demand for biological samples in research and personalized medicine, is a significant factor fueling the growth of the global biobank management systems market. A study by the National Center for Biotechnology Information in 2021 highlighted that biobank activities have been growing significantly, with the number of biobanks increasing by approximately 10% annually. As genomic research expands, the need for sophisticated systems to manage and organize large volumes of biological data and samples has grown, further boosting the demand for biobank management systems. Moreover, surge in demand for personalized medicine is notably contributing toward the market growth. This is attributed to the fact that personalized medicine relies heavily on the availability and analysis of biological samples, increasing the need for efficient biobank management systems. A study published in The Lancet in 2023 projected a 25% rise in the adoption of biobank management systems due to the growing focus on personalized medicine and tailored treatments. Furthermore, the outbreak of the COVID-19 pandemic highlighted the importance of efficient biobanking systems to manage and distribute biological samples for research, which led to an increased focus on adopting biobank management systems, thereby augmenting the market growth. In addition, integration of AI and ML technologies in biobank management systems to enhance data analysis, predictive modeling, and automated decision-making is the current trend that is significantly augmenting the market growth. Adoption of cloud-based biobank management systems is on rise, offering scalable storage solutions, improved data accessibility, and enhanced collaboration among research teams, which is a key trend strengthening the market growth. However, limited awareness of the benefits of biobank management systems coupled with lack of expertise in implementing and maintaining these systems hinder the market growth. Despite advancements in security measures, concerns over data breaches and unauthorized access to sensitive biological data can deter institutions from fully adopting digital management systems. On the contrary, innovations in data management, automation, and cloud computing have enhanced the capabilities of biobank management systems, which are expected to offer lucrative opportunities for the expansion of the global market during the forecast period. In addition, rise in investments from government bodies, research institutions, and private companies in biobanking and related technologies are contributing to the expansion of the biobank management systems market.

The global biobank management systems industry is segmented into sample type, application, and region. By sample type, the market is divided into absorbable human tissue & organ samples, plant & animal samples, and microbial samples. On the basis of application, it is classified into regenerative medicine, life science research, clinical research, and environmental research. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By sample type, the human tissue & organ samples segment dominated the market, in terms of share, in 2023.

On the basis of application, the clinical research segment was the major shareholder in 2023.

Region wise, North America held the leading position in the market in 2023.

Competition Analysis

Competitive analysis and profiles of the major players in the global biobank management systems market include Agilent Technologies, Inc., CloudLIMS Technologies Pvt. Ltd., AgileBio SARL, Modul-Bio, Autoscribe Informatics, Krishagni Solutions Pvt Ltd., Information Management Services, Inc, Technidata Inc, Qiagen N.V, and Azenta Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and gain a strong foothold in the global market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Sample Type

  • Absorbable Human Tissue Organ Samples
  • Plant Animal Samples
  • Microbial Samples

By Application

  • Regenerative Medicine
  • Life Science Research
  • Clinical Research
  • Environmental Research

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Agilent Technologies, Inc.
    • CloudLIMS Technologies Pvt. Ltd.
    • AgileBio SARL
    • Modul-Bio
    • Autoscribe Informatics
    • Krishagni Solutions Pvt Ltd
    • Information Management Services, Inc
    • Technidata Inc
    • Qiagen N.V
    • Azenta Inc

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: BIOBANK MANAGEMENT SYSTEMS MARKET, BY SAMPLE TYPE

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Sample Type
  • 4.2. Absorbable Human Tissue Organ Samples
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Plant Animal Samples
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. Microbial Samples
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country

CHAPTER 5: BIOBANK MANAGEMENT SYSTEMS MARKET, BY APPLICATION

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Application
  • 5.2. Regenerative Medicine
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Life Science Research
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country
  • 5.4. Clinical Research
    • 5.4.1. Key Market Trends, Growth Factors and Opportunities
    • 5.4.2. Market Size and Forecast, By Region
    • 5.4.3. Market Share Analysis, By Country
  • 5.5. Environmental Research
    • 5.5.1. Key Market Trends, Growth Factors and Opportunities
    • 5.5.2. Market Size and Forecast, By Region
    • 5.5.3. Market Share Analysis, By Country

CHAPTER 6: BIOBANK MANAGEMENT SYSTEMS MARKET, BY REGION

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By Region
  • 6.2. North America
    • 6.2.1. Key Market Trends and Opportunities
    • 6.2.2. Market Size and Forecast, By Sample Type
    • 6.2.3. Market Size and Forecast, By Application
    • 6.2.4. Market Size and Forecast, By Country
    • 6.2.5. U.S. Biobank Management Systems Market
      • 6.2.5.1. Market Size and Forecast, By Sample Type
      • 6.2.5.2. Market Size and Forecast, By Application
    • 6.2.6. Canada Biobank Management Systems Market
      • 6.2.6.1. Market Size and Forecast, By Sample Type
      • 6.2.6.2. Market Size and Forecast, By Application
    • 6.2.7. Mexico Biobank Management Systems Market
      • 6.2.7.1. Market Size and Forecast, By Sample Type
      • 6.2.7.2. Market Size and Forecast, By Application
  • 6.3. Europe
    • 6.3.1. Key Market Trends and Opportunities
    • 6.3.2. Market Size and Forecast, By Sample Type
    • 6.3.3. Market Size and Forecast, By Application
    • 6.3.4. Market Size and Forecast, By Country
    • 6.3.5. Germany Biobank Management Systems Market
      • 6.3.5.1. Market Size and Forecast, By Sample Type
      • 6.3.5.2. Market Size and Forecast, By Application
    • 6.3.6. France Biobank Management Systems Market
      • 6.3.6.1. Market Size and Forecast, By Sample Type
      • 6.3.6.2. Market Size and Forecast, By Application
    • 6.3.7. UK Biobank Management Systems Market
      • 6.3.7.1. Market Size and Forecast, By Sample Type
      • 6.3.7.2. Market Size and Forecast, By Application
    • 6.3.8. Italy Biobank Management Systems Market
      • 6.3.8.1. Market Size and Forecast, By Sample Type
      • 6.3.8.2. Market Size and Forecast, By Application
    • 6.3.9. Spain Biobank Management Systems Market
      • 6.3.9.1. Market Size and Forecast, By Sample Type
      • 6.3.9.2. Market Size and Forecast, By Application
    • 6.3.10. Rest of Europe Biobank Management Systems Market
      • 6.3.10.1. Market Size and Forecast, By Sample Type
      • 6.3.10.2. Market Size and Forecast, By Application
  • 6.4. Asia-Pacific
    • 6.4.1. Key Market Trends and Opportunities
    • 6.4.2. Market Size and Forecast, By Sample Type
    • 6.4.3. Market Size and Forecast, By Application
    • 6.4.4. Market Size and Forecast, By Country
    • 6.4.5. Japan Biobank Management Systems Market
      • 6.4.5.1. Market Size and Forecast, By Sample Type
      • 6.4.5.2. Market Size and Forecast, By Application
    • 6.4.6. China Biobank Management Systems Market
      • 6.4.6.1. Market Size and Forecast, By Sample Type
      • 6.4.6.2. Market Size and Forecast, By Application
    • 6.4.7. Australia Biobank Management Systems Market
      • 6.4.7.1. Market Size and Forecast, By Sample Type
      • 6.4.7.2. Market Size and Forecast, By Application
    • 6.4.8. India Biobank Management Systems Market
      • 6.4.8.1. Market Size and Forecast, By Sample Type
      • 6.4.8.2. Market Size and Forecast, By Application
    • 6.4.9. South Korea Biobank Management Systems Market
      • 6.4.9.1. Market Size and Forecast, By Sample Type
      • 6.4.9.2. Market Size and Forecast, By Application
    • 6.4.10. Rest of Asia-Pacific Biobank Management Systems Market
      • 6.4.10.1. Market Size and Forecast, By Sample Type
      • 6.4.10.2. Market Size and Forecast, By Application
  • 6.5. LAMEA
    • 6.5.1. Key Market Trends and Opportunities
    • 6.5.2. Market Size and Forecast, By Sample Type
    • 6.5.3. Market Size and Forecast, By Application
    • 6.5.4. Market Size and Forecast, By Country
    • 6.5.5. Brazil Biobank Management Systems Market
      • 6.5.5.1. Market Size and Forecast, By Sample Type
      • 6.5.5.2. Market Size and Forecast, By Application
    • 6.5.6. Saudi Arabia Biobank Management Systems Market
      • 6.5.6.1. Market Size and Forecast, By Sample Type
      • 6.5.6.2. Market Size and Forecast, By Application
    • 6.5.7. South Africa Biobank Management Systems Market
      • 6.5.7.1. Market Size and Forecast, By Sample Type
      • 6.5.7.2. Market Size and Forecast, By Application
    • 6.5.8. Rest of LAMEA Biobank Management Systems Market
      • 6.5.8.1. Market Size and Forecast, By Sample Type
      • 6.5.8.2. Market Size and Forecast, By Application

CHAPTER 7: COMPETITIVE LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top Winning Strategies
  • 7.3. Product Mapping of Top 10 Player
  • 7.4. Competitive Dashboard
  • 7.5. Competitive Heatmap
  • 7.6. Top Player Positioning, 2023

CHAPTER 8: COMPANY PROFILES

  • 8.1. Agilent Technologies, Inc.
    • 8.1.1. Company Overview
    • 8.1.2. Key Executives
    • 8.1.3. Company Snapshot
    • 8.1.4. Operating Business Segments
    • 8.1.5. Product Portfolio
    • 8.1.6. Business Performance
    • 8.1.7. Key Strategic Moves and Developments
  • 8.2. CloudLIMS Technologies Pvt. Ltd.
    • 8.2.1. Company Overview
    • 8.2.2. Key Executives
    • 8.2.3. Company Snapshot
    • 8.2.4. Operating Business Segments
    • 8.2.5. Product Portfolio
    • 8.2.6. Business Performance
    • 8.2.7. Key Strategic Moves and Developments
  • 8.3. AgileBio SARL
    • 8.3.1. Company Overview
    • 8.3.2. Key Executives
    • 8.3.3. Company Snapshot
    • 8.3.4. Operating Business Segments
    • 8.3.5. Product Portfolio
    • 8.3.6. Business Performance
    • 8.3.7. Key Strategic Moves and Developments
  • 8.4. Modul-Bio
    • 8.4.1. Company Overview
    • 8.4.2. Key Executives
    • 8.4.3. Company Snapshot
    • 8.4.4. Operating Business Segments
    • 8.4.5. Product Portfolio
    • 8.4.6. Business Performance
    • 8.4.7. Key Strategic Moves and Developments
  • 8.5. Autoscribe Informatics
    • 8.5.1. Company Overview
    • 8.5.2. Key Executives
    • 8.5.3. Company Snapshot
    • 8.5.4. Operating Business Segments
    • 8.5.5. Product Portfolio
    • 8.5.6. Business Performance
    • 8.5.7. Key Strategic Moves and Developments
  • 8.6. Krishagni Solutions Pvt Ltd
    • 8.6.1. Company Overview
    • 8.6.2. Key Executives
    • 8.6.3. Company Snapshot
    • 8.6.4. Operating Business Segments
    • 8.6.5. Product Portfolio
    • 8.6.6. Business Performance
    • 8.6.7. Key Strategic Moves and Developments
  • 8.7. Information Management Services, Inc
    • 8.7.1. Company Overview
    • 8.7.2. Key Executives
    • 8.7.3. Company Snapshot
    • 8.7.4. Operating Business Segments
    • 8.7.5. Product Portfolio
    • 8.7.6. Business Performance
    • 8.7.7. Key Strategic Moves and Developments
  • 8.8. Technidata Inc
    • 8.8.1. Company Overview
    • 8.8.2. Key Executives
    • 8.8.3. Company Snapshot
    • 8.8.4. Operating Business Segments
    • 8.8.5. Product Portfolio
    • 8.8.6. Business Performance
    • 8.8.7. Key Strategic Moves and Developments
  • 8.9. Qiagen N.V
    • 8.9.1. Company Overview
    • 8.9.2. Key Executives
    • 8.9.3. Company Snapshot
    • 8.9.4. Operating Business Segments
    • 8.9.5. Product Portfolio
    • 8.9.6. Business Performance
    • 8.9.7. Key Strategic Moves and Developments
  • 8.10. Azenta Inc
    • 8.10.1. Company Overview
    • 8.10.2. Key Executives
    • 8.10.3. Company Snapshot
    • 8.10.4. Operating Business Segments
    • 8.10.5. Product Portfolio
    • 8.10.6. Business Performance
    • 8.10.7. Key Strategic Moves and Developments
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦